MA51899A - Inhibiteurs de btk et de leurs mutants - Google Patents

Inhibiteurs de btk et de leurs mutants

Info

Publication number
MA51899A
MA51899A MA051899A MA51899A MA51899A MA 51899 A MA51899 A MA 51899A MA 051899 A MA051899 A MA 051899A MA 51899 A MA51899 A MA 51899A MA 51899 A MA51899 A MA 51899A
Authority
MA
Morocco
Prior art keywords
btk
mutants
inhibitors
Prior art date
Application number
MA051899A
Other languages
English (en)
Inventor
Yi Chen
Original Assignee
Newave Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newave Pharmaceutical Inc filed Critical Newave Pharmaceutical Inc
Publication of MA51899A publication Critical patent/MA51899A/fr

Links

Classifications

    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06QINFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q20/00Payment architectures, schemes or protocols
    • G06Q20/30Payment architectures, schemes or protocols characterised by the use of specific devices or networks
    • G06Q20/34Payment architectures, schemes or protocols characterised by the use of specific devices or networks using cards, e.g. integrated circuit [IC] cards or magnetic cards
    • G06Q20/349Rechargeable cards
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06KGRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K19/00Record carriers for use with machines and with at least a part designed to carry digital markings
    • G06K19/06Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
    • G06K19/067Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components
    • G06K19/07Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips
    • G06K19/0723Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips the record carrier comprising an arrangement for non-contact communication, e.g. wireless communication circuits on transponder cards, non-contact smart cards or RFIDs
    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06QINFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q20/00Payment architectures, schemes or protocols
    • G06Q20/30Payment architectures, schemes or protocols characterised by the use of specific devices or networks
    • G06Q20/34Payment architectures, schemes or protocols characterised by the use of specific devices or networks using cards, e.g. integrated circuit [IC] cards or magnetic cards
    • G06Q20/341Active cards, i.e. cards including their own processing means, e.g. including an IC or chip

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Business, Economics & Management (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Theoretical Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Strategic Management (AREA)
  • Accounting & Taxation (AREA)
  • General Business, Economics & Management (AREA)
  • Computer Hardware Design (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA051899A 2018-02-19 2019-02-15 Inhibiteurs de btk et de leurs mutants MA51899A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862631945P 2018-02-19 2018-02-19

Publications (1)

Publication Number Publication Date
MA51899A true MA51899A (fr) 2020-12-30

Family

ID=65685969

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051899A MA51899A (fr) 2018-02-19 2019-02-15 Inhibiteurs de btk et de leurs mutants

Country Status (12)

Country Link
US (3) US11501284B2 (fr)
EP (1) EP3755702A1 (fr)
JP (1) JP7535949B2 (fr)
KR (1) KR102861971B1 (fr)
CN (2) CN111741959B (fr)
AU (1) AU2019222475B2 (fr)
CA (1) CA3088796A1 (fr)
IL (1) IL276575B2 (fr)
MA (1) MA51899A (fr)
MX (1) MX2020008627A (fr)
SG (1) SG11202006274XA (fr)
WO (1) WO2019161152A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020008627A (es) * 2018-02-19 2020-09-21 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de btk y mutantes de los mismos.
EP3930717A1 (fr) * 2019-02-25 2022-01-05 Guangzhou Lupeng Pharmaceutical Company Ltd. Inhibiteurs de btk et leurs mutants
WO2021038540A1 (fr) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Acides cycloalkylidènecarboxyliques et dérivés en tant qu'inhibiteurs de la btk
WO2021066958A1 (fr) * 2019-10-05 2021-04-08 Newave Pharmaceutical Inc. Inhibiteurs de btk et leurs mutants
WO2021164735A1 (fr) 2020-02-20 2021-08-26 Hutchison Medipharma Limited Composés hétérocycliques hétéroaryles et leurs utilisations
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
MX2023001865A (es) 2020-08-14 2023-05-09 Guangzhou Lupeng Pharmaceutical Company Ltd Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este.
EP4214206A4 (fr) 2020-09-21 2024-10-09 Hutchison Medipharma Limited Composés hétérocycliques hétéroaryle et leurs utilisations
US20240058457A1 (en) * 2020-12-20 2024-02-22 Newave Pharmaceutical Inc. Btk degrader
CN117897388A (zh) * 2020-12-20 2024-04-16 广州麓鹏制药有限公司 Btk蛋白降解剂
CN115960124B (zh) * 2023-02-23 2025-02-18 康化(上海)新药研发有限公司 一种2-氟-3-甲酰基-吡啶-4-硼酸频哪醇酯的合成方法
AU2024320769A1 (en) 2023-08-07 2026-03-05 Guangzhou Lupeng Pharmaceutical Co., Ltd. Crystal form vi of acrylamide compound, and preparation method therefor and use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
SG10201510696RA (en) 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
CN110818724B (zh) * 2010-05-07 2020-11-13 吉利德康涅狄格有限公司 吡啶酮和氮杂吡啶酮化合物及使用方法
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
HK1218416A1 (zh) 2013-03-05 2017-02-17 F. Hoffmann-La Roche Ag 布鲁顿氏酪氨酸激酶抑制剂
MX355943B (es) 2013-06-26 2018-05-07 Abbvie Inc Carboxamidas primarias como inhibidores de btk.
WO2015050703A1 (fr) * 2013-10-04 2015-04-09 Yi Chen Inhibiteurs de la tyrosine kinase de bruton
EP3077384B1 (fr) * 2013-12-05 2017-09-06 F. Hoffmann-La Roche AG Composés de pyridone hétéroarylique et d'aza-pyridone à fonctionnalité électrophile
AU2017376580B2 (en) * 2016-12-15 2020-08-13 F. Hoffmann-La Roche Ag Process for preparing BTK inhibitors
JP2021512059A (ja) 2018-01-29 2021-05-13 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド ブルトン型チロシンキナーゼ(btk)阻害剤のe3リガーゼリガンドとのコンジュゲーションによるbtkの分解および使用方法
MX2020008627A (es) * 2018-02-19 2020-09-21 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de btk y mutantes de los mismos.
EP3930717A1 (fr) 2019-02-25 2022-01-05 Guangzhou Lupeng Pharmaceutical Company Ltd. Inhibiteurs de btk et leurs mutants
WO2021066958A1 (fr) 2019-10-05 2021-04-08 Newave Pharmaceutical Inc. Inhibiteurs de btk et leurs mutants
US20230024442A1 (en) 2019-11-08 2023-01-26 Nurix Therapeutics, Inc. Bifunctional compounds for grading btk via ubiquitin proteosome pathway

Also Published As

Publication number Publication date
MX2020008627A (es) 2020-09-21
US12086788B2 (en) 2024-09-10
IL276575A (en) 2020-09-30
KR102861971B1 (ko) 2025-09-19
WO2019161152A1 (fr) 2019-08-22
JP2021514390A (ja) 2021-06-10
US20200377478A1 (en) 2020-12-03
AU2019222475A1 (en) 2020-07-30
SG11202006274XA (en) 2020-07-29
EP3755702A1 (fr) 2020-12-30
IL276575B2 (en) 2024-05-01
KR20200122348A (ko) 2020-10-27
US20250045728A1 (en) 2025-02-06
IL276575B1 (en) 2024-01-01
JP7535949B2 (ja) 2024-08-19
CN117209502A (zh) 2023-12-12
US20230140433A1 (en) 2023-05-04
CN111741959A (zh) 2020-10-02
US11501284B2 (en) 2022-11-15
CN111741959B (zh) 2023-09-05
AU2019222475B2 (en) 2024-08-15
CA3088796A1 (fr) 2019-08-22

Similar Documents

Publication Publication Date Title
MA51899A (fr) Inhibiteurs de btk et de leurs mutants
EP3870579A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
IL283592A (en) Inhibitors of apol1 and methods of using same
IL287223A (en) Kras g12c inhibitors and methods of using the same
EP3866789A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
IL287940A (en) Fgfr inhibitors and methods of use thereof
IL271025A (en) Multibiotic agents and methods of using the same
EP3886843A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
DK3788044T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
EP3700527A4 (fr) Inhibiteurs de papd5 et leurs méthodes d'utilisation
DK3737765T4 (da) Forstærkede immunceller med dobbelt shrna og sammensætning dermed
EP3746075A4 (fr) Inhibiteurs de gcn2 et leurs utilisations
IL287751A (en) Kcnt1 inhibitors and methods of use
IL283106A (en) Erk inhibitors and uses thereof
IL287768A (en) Kcnt1 inhibitors and methods of use
EP3938369A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
IL281438A (en) Pyridazinones and methods of use thereof
HRP20251592T1 (hr) Inhibitori arginaze i metode njihove primjene
DK3710430T3 (da) Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
EP3624797A4 (fr) Inhibiteurs de kinase et leurs utilisations
HUE052468T2 (hu) Arginázgátlók és terápiás alkalmazásaik
IL283782A (en) Anellosomes and methods of use
IL286481A (en) Pyridazinones and methods of use thereof
EP3914357A4 (fr) Inhibiteurs de tyk2 et leurs utilisations